There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palatin Technologies (PTN – Research Report) and DermTech (DMTK – Research Report) with bullish sentiments.
Palatin Technologies (PTN)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Palatin Technologies, with a price target of $50.00. The company’s shares closed last Monday at $2.26, close to its 52-week low of $2.08.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of
Palatin Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $60.00, implying a 2730.2% upside from current levels. In a report issued on April 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
DermTech (DMTK)
BTIG analyst Mark Massaro reiterated a Buy rating on DermTech on May 5 and set a price target of $6.00. The company’s shares closed last Monday at $2.49, close to its 52-week low of $1.55.
According to TipRanks.com, Massaro ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
DermTech has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, which is a 170.3% upside from current levels. In a report issued on May 5, Craig-Hallum also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PTN:
